Principles of Neoplasia — Benign vs Malignant

Multistep Carcinogenesis and Clonal Evolution

• Malignant transformation requires accumulation of multiple genetic alterations (typically 4-7 critical mutations) affecting oncogenes and tumor suppressor genes
• Benign tumors typically represent early arrest in this multi-hit process, maintaining relatively few genetic alterations and often demonstrating chromosomal stability
• Malignant tumors show chromosomal instability (CIN), microsatellite instability (MSI), and accumulating mutations through positive selection of advantageous clones
• The adenoma-carcinoma sequence exemplifies this process: normal epithelium → early adenoma (APC mutations) → intermediate adenoma (KRAS activation) → late adenoma (TP53 loss) → invasive carcinoma (additional alterations enabling invasion and metastasis)

Loss of Growth Regulation and Contact Inhibition

• Benign neoplasms retain contact inhibition, responding to density-dependent growth signals and remaining organized in growth patterns
• Malignant cells lose contact inhibition through downregulation of E-cadherin (calcium-dependent adhesion molecule) and disruption of adherens junctions, enabling chaotic multilayered growth
• Telomere shortening normally limits replicative potential (Hayflick limit ~50-70 divisions); benign cells respect this constraint while malignant cells activate telomerase (95% of cancers) or ALT pathway (alternative lengthening of telomeres) to achieve replicative immortality
• RB pathway inactivation (through RB mutation, CDK4/6 upregulation, or p16 loss) allows malignant cells to bypass G1/S checkpoint, whereas benign tumors typically maintain functional RB signaling

Invasion and Basement Membrane Breach

• The basement membrane (composed of type IV collagen, laminin, nidogen, and perlecan) acts as an impermeable barrier; benign tumors never breach this structure
• Malignant transformation requires epithelial-mesenchymal transition (EMT), orchestrated by transcription factors (SNAIL, SLUG, TWIST, ZEB1/2) that downregulate E-cadherin and upregulate N-cadherin and vimentin
• Increased protease production (matrix metalloproteinases [MMPs], particularly MMP-2 and MMP-9) degrades basement membrane components and extracellular matrix
• Malignant cells upregulate VEGF and FGF to promote neoangiogenesis, enabling nutrient supply and vascular access for dissemination; benign tumors may recruit blood vessels but do not show the pathologic angiogenesis hallmarked by endothelial dysfunction and vascular leakiness

Evasion of Apoptosis and Immune Surveillance

• TP53 mutations (present in >50% of cancers) disable apoptosis induction in response to DNA damage, genomic instability, and oncogenic stress
• Upregulation of anti-apoptotic proteins (BCL-2, MCL-1) and downregulation of pro-apoptotic molecules (BAX, PUMA, NOXA) shift the balance toward survival
• Malignant cells express PD-L1, FasL, and other immunosuppressive molecules while recruiting regulatory T cells (Tregs) to create immunologically "cold" tumors
• Loss of MHC class I expression and downregulation of tumor-associated antigen presentation allow escape from cytotoxic T cell recognition
• Benign neoplasms typically maintain intact immune surveillance and apoptotic mechanisms

Angiogenic Switching and Tumor Microenvironment

• Benign tumors remain small (<2-3 mm diameter) and non-vascularized, limited by diffusion constraints; they exist in dormancy without neoangiogenesis
• The angiogenic switch (activation of pro-angiogenic signals including VEGF, bFGF, and PDGF while suppressing anti-angiogenic factors like thrombospondin and angiostatin) is a critical rate-limiting step in malignant progression
• Malignant tumors establish a desmoplastic response with recruitment of cancer-associated fibroblasts (CAFs), immune cells, and extracellular matrix remodeling that creates a tumor-supporting microenvironment
• This tumor microenvironment secretes growth factors, promotes EMT, provides nutrient and oxygen supply, and shields malignant cells from immune attack

Metastatic Cascade and Invasion-Dissemination-Colonization

• The invasion-metastasis cascade requires sequential steps: (1) local invasion through basement membrane and stroma, (2) intravasation into blood or lymphatic vessels, (3) survival in circulation (typically <1% of circulating tumor cells survive), (4) arrest at distant organs, (5) extravasation, and (6) colonization and proliferation in foreign microenvironment
• Epithelial plasticity and heterogeneity within tumors produce subclones with varying metastatic potential; selection pressures during dissemination enrich for particularly aggressive phenotypes
• Metastatic cells often acquire additional mutations enabling adaptation to distant organs, including activation of organ-specific growth factors and evasion of organ-specific immune responses
• Benign tumors lack the genetic and phenotypic alterations necessary for any step in this cascade

Genetic Alterations - Oncogenic Activation

• KRAS mutations (point mutations causing constitutive GTPase activity): present in ~30% of adenocarcinomas; associated with poor prognosis and therapeutic resistance
• MYC amplification/translocation: drives uncontrolled proliferation through transcriptional upregulation of cell cycle and metabolic genes; characteristic of Burkitt lymphoma and small cell lung carcinoma
• HER2 amplification: occurs in ~15-20% of breast cancers; drives proliferation through PI3K/AKT and MAPK pathway activation
• PI3K/AKT/mTOR pathway activation: promotes survival and proliferation; frequently altered in malignant neoplasms through PIK3CA mutations, PTEN loss, or AKT amplification

Genetic Alterations - Tumor Suppressor Loss

• TP53 mutations: the most frequently mutated gene in human cancer (>50% of malignancies); loss disables apoptosis, checkpoint control, and DNA repair; associated with Li-Fraumeni syndrome when inherited
• RB1 inactivation: disrupts G1/S checkpoint control; mutations germline in retinoblastoma, somatic in osteosarcoma, lung, and breast cancers
• APC mutations: initiating lesion in colorectal cancer pathway; loss of APC destabilizes β-catenin, promoting constitutive Wnt signaling
• BRCA1/BRCA2 mutations: critical for homologous recombination DNA repair; mutations confer 45-90% lifetime risk of breast/ovarian cancer

Carcinogenic Exposures

• Tobacco smoke: contains >70 carcinogens including nitrosamines and polycyclic aromatic hydrocarbons (PAHs); causes lung, laryngeal, esophageal, bladder, and pancreatic cancers through KRAS and TP53 mutations
• Ultraviolet radiation (UVB): causes melanoma and non-melanoma skin cancers through thymine dimers, CC→TT mutations (distinctive signature), and TP53 inactivation
• Ionizing radiation: increases cancer risk through double-strand DNA breaks; characteristic of leukemia (latency 5-10 years) and solid tumors (latency 15-40 years)
• Chemical carcinogens: asbestos (mesothelioma), benzene (acute myeloid leukemia), vinyl chloride (hepatic angiosarcoma), aflatoxins (hepatocellular carcinoma)
• Alcohol: acts as promoting agent in esophageal, laryngeal, and hepatocellular carcinomas; mechanisms include acetaldehyde toxicity, oxidative stress, and impaired DNA repair

Chronic Inflammation and Infection

• Chronic inflammatory bowel disease (IBD): ulcerative colitis and Crohn disease confer 2-8% lifetime risk of colorectal cancer through persistent TNF-α, IL-6, and ROS production driving mutagenesis
• Bacterial infection - Helicobacter pylori: causes chronic gastritis with evolution to intestinal metaplasia, dysplasia, and gastric adenocarcinoma; associated with lymphoma of mucosa-associated lymphoid tissue (MALT)
• Viral oncogenesis:
• Human papillomavirus (HPV) types 16, 18: integrate into host genome, express viral oncoproteins E6 (inactivates TP53) and E7 (inactivates RB); cause cervical, anal, oropharyngeal, and vulvar cancers
• Hepatitis B and C viruses (HBV, HCV): cause chronic hepatitis with cirrhosis and hepatocellular carcinoma; HBV encodes HBx protein promoting genomic instability
• Epstein-Barr virus (EBV): drives Burkitt lymphoma through MYC translocations and nasopharyngeal carcinoma; expresses latent membrane proteins inhibiting apoptosis
• Human T-cell lymphotropic virus-1 (HTLV-1): causes adult T-cell lymphoma through Tax protein disrupting cell cycle control
• Chronic hepatitis and cirrhosis: regardless of etiology, cirrhotic livers have 4-5% annual risk of hepatocellular carcinoma due to regenerative hyperplasia-associated mutagenesis

Hormonal Factors

• Estrogen exposure: prolonged hormone replacement therapy increases breast cancer risk by 1.3-fold; unopposed estrogen in endometrial cancer; acts through ER-mediated proliferation
• Obesity: increases cancer risk through adipokine-mediated inflammation, elevated estrogen levels (aromatase in adipose tissue), hyperinsulinemia, and IGF-1 signaling
• Reproductive factors: early menarche, late menopause, nulliparity, and late first pregnancy increase breast cancer risk through cumulative estrogen exposure

Hereditary Cancer Syndromes

• Lynch syndrome (HNPCC): germline mismatch repair (MMR) gene mutations (MLH1, MSH2, MSH6, PMS2); 80% colorectal cancer risk, 40-60% endometrial cancer risk
• Familial adenomatous polyposis (FAP): germline APC mutation; virtually 100% colorectal cancer risk by age 40 without prophylactic colectomy
• Hereditary breast and ovarian cancer syndrome: BRCA1/BRCA2 mutations; 45-90% breast cancer lifetime risk
• Li-Fraumeni syndrome: germline TP53 mutations; markedly increased risk of multiple cancer types (breast, lung, sarcoma, leukemia, brain) with early onset

Immunosuppression

• HIV infection: 30-40 times increased cancer risk; associated with Kaposi sarcoma (HHV-8), non-Hodgkin lymphoma (often CNS), and cervical cancer
• Organ transplantation: 5-10 times increased cancer risk due to chronic immunosuppression; particularly Kaposi sarcoma, squamous cell carcinoma, and lymphomas
• Chronic immunosuppressive therapy: increases lymphoma and solid tumor risk

Benign Neoplasms - Characteristic Features

• Asymptomatic incidental discovery: many benign tumors found on imaging or autopsy without clinical manifestation due to slow growth and lack of systemic effects
• Mechanical obstruction: benign tumors in anatomically constrained spaces cause localized dysfunction; example: acoustic neuroma (schwannoma) causing unilateral hearing loss and tinnitus through compression of CN VIII in cerebellopontine angle
• Organ dysfunction through displacement: benign meningiomas cause mass effect symptoms (headache, focal neurological deficits) without invasion of brain parenchyma
• Pain: typically localized to tumor site, proportional to size and degree of inflammation; differs from malignant tumors causing pain through perineural invasion and destructive invasion
• Palpable mass: benign tumors present as well-circumscribed, mobile, non-tender nodules on examination; example: lipoma as soft, mobile subcutaneous mass

• Benign adrenal adenoma: produces cortisol excess causing Cushing syndrome, or aldosterone excess causing primary hyperaldosteronism
• Benign thyroid nodule (adenoma): may produce thyroid hormone leading to thyrotoxicosis; distinguish from malignant nodule by lack of invasive features
• Acoustic neuroma/schwannoma: often asymptomatic but can produce mass effect; associated with NF2 syndrome (bilateral acoustic neuromas)

• Slow growth rate: benign tumors typically double in size over months to years; example: lipomas may remain stable for years
• Lack of systemic symptoms: benign tumors do not produce fever, weight loss, cachexia, or constitutional symptoms absent from local effects
• Spontaneous regression: rare but documented; example: hemangiomas may involute spontaneously

Malignant Neoplasms - Cardinal Clinical Features

• Fever: mediated by TNF-α, IL-1, IL-6 production by malignant cells and recruited immune cells; seen in 10-30% of advanced lymphomas and other malignancies
• Night sweats: often drenching, requiring clothing changes; pathophysiology involves cytokine-mediated elevation of temperature set point and increased metabolism
• Unintentional weight loss: typically >10% body weight over 3-6 months; multifactorial etiology including cachexia from TNF-α and IL-6, increased metabolic demands of tumor, anorexia, and malabsorption
• Fatigue and malaise: profound lack of energy disproportionate to activity level; related to tumor burden, anemia, cytokine effects, and depression

• Progressive localized pain: often worse at night, unresponsive to NSAIDs, indicates perineural invasion and local tissue destruction
• Pain from metastases: bone metastases cause sharp, localized pain; spinal metastases may cause radicular pain or myelopathy
• Visceral pain: abdominal/pelvic malignancies causing referred pain in distribution of involved spinal nerves

• Visible mass or skin changes: ulcerating lesions, bleeding, drainage suggesting epithelial malignancy; example: squamous cell carcinoma presenting as nonhealing ulcer with rolled edges and central necrosis
• Obstruction and dysfunction: malignant tumors often cause more severe and progressive obstruction due to invasion; example: pancreatic adenocarcinoma causing biliary obstruction (jaundice), gastric outlet obstruction, and splenic vein thrombosis
• Neurological deficits: from metastatic disease or mass effect; example: brain metastases causing focal weakness, seizures, cognitive changes

• Endocrine paraneoplasia: ectopic hormone production; example: small cell lung cancer producing ACTH (causing hypokalemia, hypertension) or ADH (causing hyponatremia)
• Neurological paraneoplasia: antibody-mediated

Initial evaluation

• Imaging: characterizes the lesion before any tissue is taken. Benign lesions are well-circumscribed, encapsulated, and mobile with smooth margins; malignant lesions show irregular/spiculated borders, fixation to surrounding structures, central necrosis, and destruction of adjacent bone or fascial planes.
• Tumor markers (CEA, AFP, CA 19-9, PSA, CA-125): lack the sensitivity and specificity to establish a diagnosis. They are used for monitoring response and detecting recurrence — a normal marker never excludes cancer.

Gold standard — tissue

• Histopathology of an adequate tissue specimen is definitive. Fine-needle aspiration yields cytology only and cannot demonstrate stromal invasion, so a core needle or excisional biopsy — which preserves architecture — is generally needed when the invasion question is the diagnostic issue; FNA remains first-line in specific settings such as thyroid nodule triage and confirmation of nodal metastasis.
• Cytologic features of malignancy (anaplasia): nuclear pleomorphism, hyperchromasia, increased nuclear-to-cytoplasmic ratio approaching 1:1, prominent nucleoli, atypical (tripolar/quadripolar) mitotic figures, tumor giant cells, and loss of polarity. Benign tumors are well differentiated and closely resemble the parent tissue.
• Immunohistochemistry assigns lineage when morphology is ambiguous: cytokeratin (carcinoma), vimentin (mesenchymal), S-100/SOX10 (melanoma, nerve sheath), CD45/LCA (lymphoid), chromogranin and synaptophysin (neuroendocrine). Ki-67 estimates proliferative fraction.

Classification and reporting

• WHO classification defines tumor entity; the College of American Pathologists synoptic cancer protocols standardize reporting of margins, lymphovascular invasion, and lymph node yield.
• Grade describes differentiation (e.g., Nottingham/Bloom-Richardson for breast — tubule formation, nuclear pleomorphism, mitotic count; Gleason score/ISUP Grade Group for prostate).
• Stage uses the AJCC TNM system (tumor size/depth, regional nodes, distant metastases). Stage is the stronger prognostic determinant and drives treatment; grade refines it. Benign tumors are neither graded nor staged.

Immediate stabilization — oncologic emergencies first

• Malignant spinal cord compression: give corticosteroids (dexamethasone) immediately, obtain urgent MRI of the entire spine, and consult radiation oncology/neurosurgery. Do not wait for imaging to steroid-treat.
• Hypercalcemia of malignancy: isotonic saline volume repletion plus an antiresorptive (zoledronic acid, or denosumab in renal impairment).
• Tumor lysis syndrome: aggressive hydration with rasburicase for high-risk/established disease and xanthine oxidase inhibitor (allopurinol) for prophylaxis; rasburicase is contraindicated in G6PD deficiency (hemolysis).
• Febrile neutropenia: per IDSA, high-risk patients receive an empiric IV antipseudomonal beta-lactam (cefepime, piperacillin-tazobactam, or a carbapenem) without delay; selected low-risk patients may receive oral ciprofloxacin plus amoxicillin-clavulanate.

Benign neoplasms

• Observation suffices for asymptomatic, radiographically classic lesions.
• Complete local excision is curative and is indicated for mass effect, hormone hypersecretion, cosmetic concern, or diagnostic uncertainty.

Malignant neoplasms — NCCN-directed, stage-based

• Surgical resection with histologically negative margins is the mainstay of curative therapy for most localized solid tumors, but definitive radiation or chemoradiation is curative in selected sites (anal squamous cell carcinoma, cervical cancer, many head and neck cancers, localized prostate cancer, and medically inoperable early-stage NSCLC treated with SBRT).
• Nodal assessment: sentinel lymph node biopsy where validated (breast cancer, melanoma; also selected vulvar and endometrial disease). Completion nodal dissection after a positive sentinel node is no longer routine in either breast cancer or melanoma.
• Radiation therapy: definitive for radiosensitive tumors, adjuvant to sterilize the operative bed, or palliative for painful bone metastases and cord compression.
• Cytotoxic chemotherapy: neoadjuvant to downstage and permit organ preservation, or adjuvant to eradicate micrometastatic disease.
• Targeted and biologic therapy: anti-HER2 monoclonal antibody (trastuzumab), endocrine therapy (tamoxifen, aromatase inhibitors), PARP inhibitors in BRCA-mutated disease, and immune checkpoint inhibitors (pembrolizumab) for MSI-high/mismatch-repair-deficient tumors.
• Risk-reducing surgery per NCCN genetic/familial guidelines: prophylactic colectomy in FAP, risk-reducing mastectomy and salpingo-oophorectomy in BRCA carriers.

Contraindicated

• Enucleating ("shelling out") a soft-tissue sarcoma — this leaves microscopic disease and seeds the compartment.
• Live attenuated vaccines during active myelosuppressive therapy.
• Anthracyclines beyond cumulative dose limits, and bleomycin with high-flow oxygen exposure.

Complications of the neoplasm itself

• Local invasion and obstruction: destructive growth occludes hollow viscera (biliary obstruction with painless jaundice, bowel obstruction, post-obstructive pneumonia). Benign tumors obstruct by compression only.
• Hemorrhage and ulceration: tumor outgrows its blood supply or erodes a vessel — signaled by iron-deficiency anemia, hemoptysis, or hematochezia.
• Metastasis: the definitive marker of malignancy; bone lesions produce pathologic fracture and hypercalcemia, brain lesions produce seizures and focal deficits, liver lesions produce hepatomegaly and cholestasis.
• Cancer cachexia: TNF-α/IL-6-driven proteolysis and lipolysis producing sarcopenia that does not reverse with feeding.
• Trousseau syndrome: tumor tissue factor generates a hypercoagulable state — migratory superficial thrombophlebitis, classically with pancreatic adenocarcinoma.
• Emergencies: spinal cord compression (back pain preceding weakness, bowel/bladder dysfunction), SVC syndrome (facial plethora, distended neck veins), hypercalcemia (PTHrP-mediated; confusion, short QT), and spontaneous tumor lysis in bulky, high-turnover lymphomas/leukemias.

Complications of treatment

• Myelosuppression: nadir neutropenia predisposes to sepsis; fever in a neutropenic patient is an emergency.
• Anthracycline cardiotoxicity: free-radical myocyte injury causing dose-dependent, often irreversible dilated cardiomyopathy — signaled by a falling LVEF on surveillance echocardiography.
• Cisplatin: proximal tubular injury and ototoxicity (high-frequency hearing loss); vincristine: axonal peripheral neuropathy with loss of ankle reflexes; cyclophosphamide: acrolein-mediated hemorrhagic cystitis (prevented with mesna and hydration) and later urothelial carcinoma; bleomycin: pulmonary fibrosis with a restrictive pattern and reduced DLCO.
• Second malignancy: alkylating agents and topoisomerase II inhibitors cause therapy-related MDS/AML; therapeutic radiation causes angiosarcoma in the irradiated field and sarcomas after long latency.
• Immune-related adverse events from checkpoint inhibitors: colitis, hypophysitis, thyroiditis, pneumonitis, hepatitis — managed with high-dose corticosteroids.
• Surgical: axillary dissection causes lymphedema; wide resection risks nerve injury and functional loss.

• Invasion through the basement membrane is the defining feature of malignancy. Full-thickness dysplasia with an intact basement membrane is carcinoma in situ — no metastatic potential, cured by complete excision. This is the single distinction most stems hinge on.
• Metastasis is the most reliable single indicator that a tumor is malignant, but its absence proves nothing; many malignancies present localized. Do not use size, growth rate, or symptom burden alone to call a lesion benign.
• The best next step for a suspicious mass is tissue, not another imaging study or a tumor marker. For a follicular thyroid lesion specifically, FNA cannot separate follicular adenoma from carcinoma — the distinction requires capsular or vascular invasion on the resected specimen, so lobectomy is the answer.
• Stage beats grade for prognosis. TNM stage (AJCC) drives treatment; grade (differentiation) refines it. A well-differentiated tumor with distant metastases is still stage IV.
• "-oma" is not a safety word. Lymphoma, melanoma, seminoma, mesothelioma, glioblastoma, hepatoma, and myeloma are all malignant. Conversely, hamartoma is disorganized native tissue and choristoma is normal tissue in an ectopic site — neither is a true neoplasm.
• Route of spread: carcinomas typically disseminate first via lymphatics, sarcomas hematogenously. The examiner's exception set — renal cell carcinoma, hepatocellular carcinoma, follicular thyroid carcinoma, and choriocarcinoma — are carcinomas that spread hematogenously.
• Metastases outnumber primary tumors in brain, liver, and bone. Multiple lesions at the gray-white junction are metastatic until proven otherwise.
• Common distractor: attributing anaplasia, atypical mitoses, or tumor giant cells to a benign lesion. Benign neoplasms are well differentiated, resemble the parent tissue, and show few, normal-appearing mitoses.